Dr Morie Gertz speaks to ecancer about his talk at IMW 2021.
He addresses the topic of whether every transplant eligible NDMM patient should receive a transplant or not.
Initially, he explains the background behind this discussion. He then talks about how the goal of therapy is MRD negativity.
Dr Gertz quotes data from studies where combinations of non-cross agents are used and the role of stem cell transfer declines. He says that the non-transplant regiment has shown minimum MRD.
He concludes by explaining why through multiple novel agents minimum negativity can be achieved.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.